- PIMJETMI is a new once-daily oral systemic treatment option for certain U.S. patients with symptomatic tenosynovial giant cell tumor (TGCT)
- In the Phase 3 MANEUVER trial, PIMJETMI demonstrated early1 and durable2 tumor response with clinically meaningful improvements in all clinical outcome assessments, including physical function and pain
- PIMJETMI has shown high objective response rate (ORR) with a manageable safety profile
Not intended for Canada-, UK- or US-based media







